Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study

BACKGROUND: This study focused on comparing the safety and therapeutic effects between icotinib monotherapy and icotinib plus bevacizumab combined therapy in non‐small cell lung cancer (NSCLC) cases harboring EGFR mutations. METHODS: Data were collected retrospectively from the Cancer Institute and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhansheng, Zhang, Jing, Sun, Haiyan, Wang, Cong, Zhang, Yu, Li, Yanyang, Pan, Zhanyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410520/
https://www.ncbi.nlm.nih.gov/pubmed/34255422
http://dx.doi.org/10.1111/1759-7714.14079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410520/
https://www.ncbi.nlm.nih.gov/pubmed/34255422
http://dx.doi.org/10.1111/1759-7714.14079

Ejemplares similares